Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab in children aged 5 to 11 years with homozygous familial hypercholesterolemia
NL-OMON52413Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of evinacumab in homozygous familial hypercholesterolemia (HoFH) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Pharmacokinetic parameters of evinacumab and Percent change in calculated LDL-C from baseline to week 24. Started Nov 2020; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON52413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52413.